OTUD6B-AS1 was demonstrated to indicate poor prognosis in ovarian cancer, clear cell renal cell carcinoma (ccRCC), and breast cancer (as an immune-related lncRNA) while its overexpression inhibited ccRCC proliferation (Wang G. et al., 2019; Li and Zhan, 2019; Ma et al., 2020). Here, OTUD6B is linked to breast carcinoma.